Literature DB >> 14770299

Alexander disease: putative mechanisms of an astrocytic encephalopathy.

C Mignot1, O Boespflug-Tanguy, A Gelot, A Dautigny, D Pham-Dinh, D Rodriguez.   

Abstract

Alexander disease (AXD) is the first primary astrocytic disorder. This encephalopathy is caused by dominant mutations in the glial fibrillary acidic protein (GFAP) gene, encoding the main intermediate filament of astrocyte. Pathologically, this neurodegenerative disease is characterised by dystrophic astrocytes containing intermediate filament aggregates associated with myelin abnormalities. More than 20 GFAP mutations have been reported. Many of them cluster in highly conserved regions between several intermediate filaments. Contrary to other intermediate filament-related diseases, AXD seems to be the consequence of a toxic gain of function induced by aggregates. This is supported by the phenotype of mice overexpressing human GFAP. Nevertheless, GFAP null mice display myelin abnormalities and blood-brain barrier dysfunction that are present in AXD. Given the pivotal role of astrocytes in brain physiology, there are many possibilities for astrocytes to dysfunction and to impair the functions of other cells. Physiopathological hypotheses are discussed in the frame of AXD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14770299     DOI: 10.1007/s00018-003-3143-3

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  31 in total

Review 1.  The clinical spectrum of late-onset Alexander disease: a systematic literature review.

Authors:  Pietro Balbi; Silvana Salvini; Cira Fundarò; Giuseppe Frazzitta; Roberto Maestri; Dibo Mosah; Carla Uggetti; GianPietro Sechi
Journal:  J Neurol       Date:  2010-08-20       Impact factor: 4.849

Review 2.  Discrepancy between neuroimaging findings and clinical phenotype in Alexander disease.

Authors:  A Dinopoulos; J R Gorospe; J C Egelhoff; K M Cecil; P Nicolaidou; P Morehart; T DeGrauw
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

3.  Alexander disease causing mutations in the C-terminal domain of GFAP are deleterious both to assembly and network formation with the potential to both activate caspase 3 and decrease cell viability.

Authors:  Yi-Song Chen; Suh-Ciuan Lim; Mei-Hsuan Chen; Roy A Quinlan; Ming-Der Perng
Journal:  Exp Cell Res       Date:  2011-07-02       Impact factor: 3.905

Review 4.  GFAP and its role in Alexander disease.

Authors:  Roy A Quinlan; Michael Brenner; James E Goldman; Albee Messing
Journal:  Exp Cell Res       Date:  2007-04-06       Impact factor: 3.905

5.  Identification of a novel nonsense mutation in the rod domain of GFAP that is associated with Alexander disease.

Authors:  Tai-Seung Nam; Jin Hee Kim; Chi-Hsuan Chang; Woong Yoon; Yoon Seok Jung; Sa-Yoon Kang; Boo Ahn Shin; Ming-Der Perng; Seok-Yong Choi; Myeong-Kyu Kim
Journal:  Eur J Hum Genet       Date:  2014-04-23       Impact factor: 4.246

Review 6.  Systematic approaches to central nervous system myelin.

Authors:  Patricia de Monasterio-Schrader; Olaf Jahn; Stefan Tenzer; Sven P Wichert; Julia Patzig; Hauke B Werner
Journal:  Cell Mol Life Sci       Date:  2012-03-23       Impact factor: 9.261

7.  Ceftriaxone for Alexander's Disease: A Four-Year Follow-Up.

Authors:  GianPietro Sechi; Isabella Ceccherini; Tiziana Bachetti; Giovanni A Deiana; Elia Sechi; Pietro Balbi
Journal:  JIMD Rep       Date:  2012-10-13

8.  Properties of astrocytes cultured from GFAP over-expressing and GFAP mutant mice.

Authors:  Woosung Cho; Albee Messing
Journal:  Exp Cell Res       Date:  2008-12-29       Impact factor: 3.905

9.  Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia.

Authors:  Amy E Steffek; Robert E McCullumsmith; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2008-06-17       Impact factor: 4.939

Review 10.  Oligodendrocytes: biology and pathology.

Authors:  Monika Bradl; Hans Lassmann
Journal:  Acta Neuropathol       Date:  2009-10-22       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.